Global Artificial Blood Market Overview: 2019-2027

The Global Artificial Blood Market size was valued at USD XX billion in 2019 and is expected to reach at a compound annual growth rate (CAGR) of XX% from 2019 to 2027. Artificial blood or the blood surrogates is a substance used to mimic and fulfill some functions of biological blood, usually in the oxygen-carrying sense. The main aim of artificial blood is to provide an alternative to blood transfusion, which is transferring blood or blood-based products from one person into another. The report on the Global Artificial Blood Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of comprehensive research. The report gives a complete market analysis for the forecast period from 2019 to 2027. The market is divided into various segments with an in-depth outlook of the competitors and a listing of the profiled key players. Leading players in the global artificial blood market include Therapure Biopharma Inc., Sanguine Biosciences, Northfield Laboratories Inc., Baxter Healthcare Corp., and Alliance Pharmaceutical. The market size in terms of revenue and volume is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints. Global Artificial Blood Market Dynamic Artificial blood allows for immediate full capacity oxygen transport, as opposed to transfused blood which requires about 24 hours to reach full oxygen transport capacity due to 2, 3- diphosphoglycerate depletion. Also, oxygen-carrying artificial blood substitutes make the natural replenishment of lost red blood cells until blood is naturally replenished. This drives the global artificial blood market in the forecast period. Two main advantages of artificial blood are, it can be stored for a much longer period and kept at room temperature, which captures the attention of professional for further research & development in artificial blood products. Artificial blood have additional beneficiaries as compared to conventional blood transfusion, like safe to use, compatible in the human body, and able to transport and release oxygen where needed. The another factors that boost the global artificial blood market as they are also storable and durable for long time periods, free of pathogens and toxins which would produce an immune system response in the body. Artificial blood is specially used in the treatment of patients suffering from trauma situation, hence upsurge population suffering from heart and kidney disorders foster the market growth in the forecast period. In battlefield scenarios, it is often impossible to administer conventional blood transfusion methods. In that case, medical care in the armed services would be benefited from artificial blood, which is an easy way to manage blood supply in an efficient way with less time. These all reasons are helping to grow the artificial blood market globally. The Artificial Blood Market has been segmented based on application, distribution channel and region. By Application • Cardiovascular Diseases • Malignant Neoplasma • Injuries • Neonatal Conditions • Organ Transplant • Maternal Condition Global Artificial Blood Market Presence of numerous numbers of patients with cardiovascular diseases is driving the global artificial blood market by 2027. Cardiovascular diseases are the leading cause of death worldwide hence to save the life of patients, doctors mostly prefer artificial blood replacement in treatment and cure. If a patient loses too much blood during a traumatic injury or a surgical operation, then artificial blood replacement therapy helps to restore normal blood circulation and reduce the risk of future heart attacks and strokes. Artificial blood acts as a life-sustaining fluid, which offers the promise of new and important life-saving medical treatments. As a result, the cardiovascular diseases segment commands the artificial blood market & share the XX% of revenue in the total market. By Distribution Channel • Hospitals • Clinics • Blood banks Hospital Segment commands the artificial blood market and share the XX% of revenue in total market. The hospitals segment is expected to grow in artificial blood market due to an increase in the number of cardiac surgeries. More complex heart diseases encountered and higher frequency of neonates suffering from heart disorders, which requires blood transfusion technique, which drives the global market during the forecast period. Artificial blood has become the mainstay of treatment for many cardiac lesions and anemic conditions in the growing pediatric population, due to favorable outcomes, better safety, and low risk of infection. The hemoglobin-based products gain popularity in the artificial blood market, as it shows the effective results in the closure of anatomic lesions, the use of artificial blood for maintaining vessel patency has expanded the spectrum of heart diseases that can be treated this way, while improving therapeutic technique. By Region • North America • Europe • Asia-Pacific • MEA & Africa • Latin America Global Artificial Blood Market 1 Europe is expected to command largest market share of XX% by 2027. North America dominates the artificial blood substitutes market by the factors such as, presence of a well-established healthcare system in countries like the U.S. and Canada and high expenditure on healthcare research and private healthcare sector. Donations are increasing by about 2-3% annually in the United States and demand is also climbing 6%-8%, as an aging population requires more operations that often involve blood transfusion, which commanded the largest market share of xx% by 2027. The presence of a large number of patients with disorders such as malignant neoplasms, cancer, cardiovascular diseases, organ transplants, and neonatal conditions are the factors driving the demand for artificial blood market from North America. Middle East and Africa is expected to command second largest market share of XX% by 2027. Blood transfusion is the second-largest source of new HIV infections in Nigeria, which creates the opportunity for global market growth in this region to reduce the infections. In certain regions of southern Africa, 40% of the population has HIV/AIDS, although testing is not feasible. In this case, artificial blood is the best solution for blood-substitutes that would be incredibly beneficial in this region.

Key Players Operating in Global Artificial Blood Market Includes

• Therapure Biopharma Inc. • Sanguine Biosciences • Northfield Laboratories Inc. • Baxter Healthcare Corp. • Alliance Pharmaceutical • FLUORO2 Therapeutics • Alpha Therapeutic Corp. • Kalocyte • Hemarina • Green Cross Corp. • Biopure Corp • Sangart Corporation
Global Artificial Blood Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Artificial Blood Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Artificial Blood Market Analysis and Forecast 6.1. Artificial Blood Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Artificial Blood Market Analysis and Forecast, By Application 7.1. Introduction and Definition 7.2. Key Findings 7.3. Artificial Blood Market Value Share Analysis, By Application 7.4. Artificial Blood Market Size (US$ Mn) Forecast, By Application 7.5. Artificial Blood Market Analysis, By Application 7.6. Artificial Blood Market Attractiveness Analysis, By Application 8. Global Artificial Blood Market Analysis and Forecast, By Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Artificial Blood Market Value Share Analysis, By Distribution Channel 8.4. Artificial Blood Market Size (US$ Mn) Forecast, By Distribution Channel 8.5. Artificial Blood Market Analysis, By Distribution Channel 8.6. Artificial Blood Market Attractiveness Analysis, By Distribution Channel 9. Global Artificial Blood Market Analysis, By Region 9.1. Artificial Blood Market Value Share Analysis, By Region 9.2. Artificial Blood Market Size (US$ Mn) Forecast, By Region 9.3. Artificial Blood Market Attractiveness Analysis, By Region 10. North America Artificial Blood Market Analysis 10.1. Key Findings 10.2. North America Artificial Blood Market Overview 10.3. North America Artificial Blood Market Value Share Analysis, By Application 10.4. North America Artificial Blood Market Forecast, By Application 10.4.1. Cardiovascular Diseases 10.4.2. Malignant Neoplasma 10.4.3. Injuries 10.4.4. Neonatal Conditions 10.4.5. Organ Transplant 10.4.6. Maternal Condition 10.5. North America Artificial Blood Market Value Share Analysis, By Distribution Channel 10.6. North America Artificial Blood Market Forecast, By Distribution Channel 10.6.1. Hospitals 10.6.2. Clinics 10.6.3. Blood banks 10.7. North America Artificial Blood Market Value Share Analysis, By Country 10.8. North America Artificial Blood Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America Artificial Blood Market Analysis, By Country 10.10. U.S. Artificial Blood Market Forecast, By Application 10.10.1. Cardiovascular Diseases 10.10.2. Malignant Neoplasma 10.10.3. Injuries 10.10.4. Neonatal Conditions 10.10.5. Organ Transplant 10.10.6. Maternal Condition 10.11. U.S. Artificial Blood Market Forecast, By Distribution Channel 10.11.1. Hospitals 10.11.2. Clinics 10.11.3. Blood banks 10.12. Canada Artificial Blood Market Forecast, By Application 10.12.1. Cardiovascular Diseases 10.12.2. Malignant Neoplasma 10.12.3. Injuries 10.12.4. Neonatal Conditions 10.12.5. Organ Transplant 10.12.6. Maternal Condition 10.13. Canada Artificial Blood Market Forecast, By Distribution Channel 10.13.1. Hospitals 10.13.2. Clinics 10.13.3. Blood banks 10.14. Mexico Artificial Blood Market Forecast, By Application 10.14.1. Cardiovascular Diseases 10.14.2. Malignant Neoplasma 10.14.3. Injuries 10.14.4. Neonatal Conditions 10.14.5. Organ Transplant 10.14.6. Maternal Condition 10.15. Mexico Artificial Blood Market Forecast, By Distribution Channel 10.15.1. Hospitals 10.15.2. Clinics 10.15.3. Blood banks 10.16. North America Artificial Blood Market Attractiveness Analysis 10.16.1. By Application 10.16.2. By Distribution Channel 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe Artificial Blood Market Analysis 11.1. Key Findings 11.2. Europe Artificial Blood Market Overview 11.3. Europe Artificial Blood Market Value Share Analysis, By Application 11.4. Europe Artificial Blood Market Forecast, By Application 11.4.1. Cardiovascular Diseases 11.4.2. Malignant Neoplasma 11.4.3. Injuries 11.4.4. Neonatal Conditions 11.4.5. Organ Transplant 11.4.6. Maternal Condition 11.5. Europe Artificial Blood Market Value Share Analysis, By Distribution Channel 11.6. Europe Artificial Blood Market Forecast, By Distribution Channel 11.6.1. Hospitals 11.6.2. Clinics 11.6.3. Blood banks 11.7. Europe Artificial Blood Market Value Share Analysis, By Country 11.8. Europe Artificial Blood Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany Artificial Blood Market Forecast, By Application 11.9.1. Cardiovascular Diseases 11.9.2. Malignant Neoplasma 11.9.3. Injuries 11.9.4. Neonatal Conditions 11.9.5. Organ Transplant 11.9.6. Maternal Condition 11.10. Germany Artificial Blood Market Forecast, By Distribution Channel 11.10.1. Hospitals 11.10.2. Clinics 11.10.3. Blood banks 11.11. U.K. Artificial Blood Market Forecast, By Application 11.11.1. Cardiovascular Diseases 11.11.2. Malignant Neoplasma 11.11.3. Injuries 11.11.4. Neonatal Conditions 11.11.5. Organ Transplant 11.11.6. Maternal Condition 11.12. U.K. Artificial Blood Market Forecast, By Distribution Channel 11.12.1. Hospitals 11.12.2. Clinics 11.12.3. Blood banks 11.13. France Artificial Blood Market Forecast, By Application 11.13.1. Cardiovascular Diseases 11.13.2. Malignant Neoplasma 11.13.3. Injuries 11.13.4. Neonatal Conditions 11.13.5. Organ Transplant 11.13.6. Maternal Condition 11.14. France Artificial Blood Market Forecast, By Distribution Channel 11.14.1. Hospitals 11.14.2. Clinics 11.14.3. Blood banks 11.15. Italy Artificial Blood Market Forecast, By Application 11.15.1. Cardiovascular Diseases 11.15.2. Malignant Neoplasma 11.15.3. Injuries 11.15.4. Neonatal Conditions 11.15.5. Organ Transplant 11.15.6. Maternal Condition 11.16. Italy Artificial Blood Market Forecast, By Distribution Channel 11.16.1. Hospitals 11.16.2. Clinics 11.16.3. Blood banks 11.17. Spain Artificial Blood Market Forecast, By Application 11.17.1. Cardiovascular Diseases 11.17.2. Malignant Neoplasma 11.17.3. Injuries 11.17.4. Neonatal Conditions 11.17.5. Organ Transplant 11.17.6. Maternal Condition 11.18. Spain Artificial Blood Market Forecast, By Distribution Channel 11.18.1. Hospitals 11.18.2. Clinics 11.18.3. Blood banks 11.19. Sweden Artificial Blood Market Forecast, By Application 11.19.1. Cardiovascular Diseases 11.19.2. Malignant Neoplasma 11.19.3. Injuries 11.19.4. Neonatal Conditions 11.19.5. Organ Transplant 11.19.6. Maternal Condition 11.20. Sweden Artificial Blood Market Forecast, By Distribution Channel 11.20.1. Hospitals 11.20.2. Clinics 11.20.3. Blood banks 11.21. CIS countries Artificial Blood Market Forecast, By Application 11.21.1. Cardiovascular Diseases 11.21.2. Malignant Neoplasma 11.21.3. Injuries 11.21.4. Neonatal Conditions 11.21.5. Organ Transplant 11.21.6. Maternal Condition 11.22. CIS countries Artificial Blood Market Forecast, By Distribution Channel 11.22.1. Hospitals 11.22.2. Clinics 11.22.3. Blood banks 11.23. Rest of Europe Artificial Blood Market Forecast, By Application 11.23.1. Cardiovascular Diseases 11.23.2. Malignant Neoplasma 11.23.3. Injuries 11.23.4. Neonatal Conditions 11.23.5. Organ Transplant 11.23.6. Maternal Condition 11.24. Rest of Europe Artificial Blood Market Forecast, By Distribution Channel 11.24.1. Hospitals 11.24.2. Clinics 11.24.3. Blood banks 11.25. Europe Artificial Blood Market Attractiveness Analysis 11.25.1. By Distribution Channel 11.25.2. By Application 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific Artificial Blood Market Analysis 12.1. Key Findings 12.2. Asia Pacific Artificial Blood Market Overview 12.3. Asia Pacific Artificial Blood Market Value Share Analysis, By Application 12.4. Asia Pacific Artificial Blood Market Forecast, By Application 12.4.1. Cardiovascular Diseases 12.4.2. Malignant Neoplasma 12.4.3. Injuries 12.4.4. Neonatal Conditions 12.4.5. Organ Transplant 12.4.6. Maternal Condition 12.5. Asia Pacific Artificial Blood Market Value Share Analysis, By Distribution Channel 12.6. Asia Pacific Artificial Blood Market Forecast, By Distribution Channel 12.6.1. Hospitals 12.6.2. Clinics 12.6.3. Blood banks 12.7. Asia Pacific Artificial Blood Market Value Share Analysis, By Country 12.8. Asia Pacific Artificial Blood Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific Artificial Blood Market Analysis, By Country 12.10. China Artificial Blood Market Forecast, By Application 12.10.1. Cardiovascular Diseases 12.10.2. Malignant Neoplasma 12.10.3. Injuries 12.10.4. Neonatal Conditions 12.10.5. Organ Transplant 12.10.6. Maternal Condition 12.11. China Artificial Blood Market Forecast, By Distribution Channel 12.11.1. Hospitals 12.11.2. Clinics 12.11.3. Blood banks 12.12. India Artificial Blood Market Forecast, By Application 12.12.1. Cardiovascular Diseases 12.12.2. Malignant Neoplasma 12.12.3. Injuries 12.12.4. Neonatal Conditions 12.12.5. Organ Transplant 12.12.6. Maternal Condition 12.13. India Artificial Blood Market Forecast, By Distribution Channel 12.13.1. Hospitals 12.13.2. Clinics 12.13.3. Blood banks 12.14. Japan Artificial Blood Market Forecast, By Application 12.14.1. Cardiovascular Diseases 12.14.2. Malignant Neoplasma 12.14.3. Injuries 12.14.4. Neonatal Conditions 12.14.5. Organ Transplant 12.14.6. Maternal Condition 12.15. Japan Artificial Blood Market Forecast, By Distribution Channel 12.15.1. Hospitals 12.15.2. Clinics 12.15.3. Blood banks 12.16. South Korea Artificial Blood Market Forecast, By Application 12.16.1. Cardiovascular Diseases 12.16.2. Malignant Neoplasma 12.16.3. Injuries 12.16.4. Neonatal Conditions 12.16.5. Organ Transplant 12.16.6. Maternal Condition 12.17. South Korea Artificial Blood Market Forecast, By Distribution Channel 12.17.1. Hospitals 12.17.2. Clinics 12.17.3. Blood banks 12.18. Australia Artificial Blood Market Forecast, By Application 12.18.1. Cardiovascular Diseases 12.18.2. Malignant Neoplasma 12.18.3. Injuries 12.18.4. Neonatal Conditions 12.18.5. Organ Transplant 12.18.6. Maternal Condition 12.19. Australia Artificial Blood Market Forecast, By Distribution Channel 12.19.1. Hospitals 12.19.2. Clinics 12.19.3. Blood banks 12.20. ASEAN Artificial Blood Market Forecast, By Application 12.20.1. Cardiovascular Diseases 12.20.2. Malignant Neoplasma 12.20.3. Injuries 12.20.4. Neonatal Conditions 12.20.5. Organ Transplant 12.20.6. Maternal Condition 12.21. ASEAN Artificial Blood Market Forecast, By Distribution Channel 12.21.1. Hospitals 12.21.2. Clinics 12.21.3. Blood banks 12.22. Rest of Asia Pacific Artificial Blood Market Forecast, By Application 12.22.1. Cardiovascular Diseases 12.22.2. Malignant Neoplasma 12.22.3. Injuries 12.22.4. Neonatal Conditions 12.22.5. Organ Transplant 12.22.6. Maternal Condition 12.23. Rest of Asia Pacific Artificial Blood Market Forecast, By Distribution Channel 12.23.1. Hospitals 12.23.2. Clinics 12.23.3. Blood banks 12.24. Asia Pacific Artificial Blood Market Attractiveness Analysis 12.24.1. By Application 12.24.2. By Distribution Channel 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa Artificial Blood Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Artificial Blood Market Overview 13.3. Middle East & Africa Artificial Blood Market Value Share Analysis, By Application 13.4. Middle East & Africa Artificial Blood Market Forecast, By Application 13.4.1. Cardiovascular Diseases 13.4.2. Malignant Neoplasma 13.4.3. Injuries 13.4.4. Neonatal Conditions 13.4.5. Organ Transplant 13.4.6. Maternal Condition 13.5. Middle East & Africa Artificial Blood Market Value Share Analysis, By Distribution Channel 13.6. Middle East & Africa Artificial Blood Market Forecast, By Distribution Channel 13.6.1. Hospitals 13.6.2. Clinics 13.6.3. Blood banks 13.7. Middle East & Africa Artificial Blood Market Value Share Analysis, By Country 13.8. Middle East & Africa Artificial Blood Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa Artificial Blood Market Analysis, By Country 13.10. GCC Countries Artificial Blood Market Forecast, By Application 13.10.1. Cardiovascular Diseases 13.10.2. Malignant Neoplasma 13.10.3. Injuries 13.10.4. Neonatal Conditions 13.10.5. Organ Transplant 13.10.6. Maternal Condition 13.11. GCC Countries Artificial Blood Market Forecast, By Distribution Channel 13.11.1. Hospitals 13.11.2. Clinics 13.11.3. Blood banks 13.12. South Africa Artificial Blood Market Forecast, By Application 13.12.1. Cardiovascular Diseases 13.12.2. Malignant Neoplasma 13.12.3. Injuries 13.12.4. Neonatal Conditions 13.12.5. Organ Transplant 13.12.6. Maternal Condition 13.13. South Africa Artificial Blood Market Forecast, By Distribution Channel 13.13.1. Hospitals 13.13.2. Clinics 13.13.3. Blood banks 13.14. Nigeria Artificial Blood Market Forecast, By Application 13.14.1. Cardiovascular Diseases 13.14.2. Malignant Neoplasma 13.14.3. Injuries 13.14.4. Neonatal Conditions 13.14.5. Organ Transplant 13.14.6. Maternal Condition 13.15. Nigeria Artificial Blood Market Forecast, By Distribution Channel 13.15.1. Hospitals 13.15.2. Clinics 13.15.3. Blood banks 13.16. Egypt Artificial Blood Market Forecast, By Application 13.16.1. Cardiovascular Diseases 13.16.2. Malignant Neoplasma 13.16.3. Injuries 13.16.4. Neonatal Conditions 13.16.5. Organ Transplant 13.16.6. Maternal Condition 13.17. Egypt Artificial Blood Market Forecast, By Distribution Channel 13.17.1. Hospitals 13.17.2. Clinics 13.17.3. Blood banks 13.18. Rest of Middle East & Africa Artificial Blood Market Forecast, By Application 13.18.1. Cardiovascular Diseases 13.18.2. Malignant Neoplasma 13.18.3. Injuries 13.18.4. Neonatal Conditions 13.18.5. Organ Transplant 13.18.6. Maternal Condition 13.19. Rest of Middle East & Africa Artificial Blood Market Forecast, By Distribution Channel 13.19.1. Hospitals 13.19.2. Clinics 13.19.3. Blood banks 13.20. Middle East & Africa Artificial Blood Market Attractiveness Analysis 13.20.1. By Application 13.20.2. By Distribution Channel 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America Artificial Blood Market Analysis 14.1. Key Findings 14.2. South America Artificial Blood Market Overview 14.3. South America Artificial Blood Market Value Share Analysis, By Application 14.4. South America Artificial Blood Market Forecast, By Application 14.4.1. Cardiovascular Diseases 14.4.2. Malignant Neoplasma 14.4.3. Injuries 14.4.4. Neonatal Conditions 14.4.5. Organ Transplant 14.4.6. Maternal Condition 14.5. South America Artificial Blood Market Value Share Analysis, By Distribution Channel 14.6. South America Artificial Blood Market Forecast, By Distribution Channel 14.6.1. Hospitals 14.6.2. Clinics 14.6.3. Blood banks 14.7. South America Artificial Blood Market Value Share Analysis, By Country 14.8. South America Artificial Blood Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America Artificial Blood Market Analysis, By Country 14.10. Brazil Artificial Blood Market Forecast, By Application 14.10.1. Cardiovascular Diseases 14.10.2. Malignant Neoplasma 14.10.3. Injuries 14.10.4. Neonatal Conditions 14.10.5. Organ Transplant 14.10.6. Maternal Condition 14.11. Brazil Artificial Blood Market Forecast, By Distribution Channel 14.11.1. Hospitals 14.11.2. Clinics 14.11.3. Blood banks 14.12. Colombia Artificial Blood Market Forecast, By Application 14.12.1. Cardiovascular Diseases 14.12.2. Malignant Neoplasma 14.12.3. Injuries 14.12.4. Neonatal Conditions 14.12.5. Organ Transplant 14.12.6. Maternal Condition 14.13. Colombia Artificial Blood Market Forecast, By Distribution Channel 14.13.1. Hospitals 14.13.2. Clinics 14.13.3. Blood banks 14.14. Argentina Artificial Blood Market Forecast, By Application 14.14.1. Cardiovascular Diseases 14.14.2. Malignant Neoplasma 14.14.3. Injuries 14.14.4. Neonatal Conditions 14.14.5. Organ Transplant 14.14.6. Maternal Condition 14.15. Argentina Artificial Blood Market Forecast, By Distribution Channel 14.15.1. Hospitals 14.15.2. Clinics 14.15.3. Blood banks 14.16. Rest of South America Artificial Blood Market Forecast, By Application 14.16.1. Cardiovascular Diseases 14.16.2. Malignant Neoplasma 14.16.3. Injuries 14.16.4. Neonatal Conditions 14.16.5. Organ Transplant 14.16.6. Maternal Condition 14.17. Rest of South America Artificial Blood Market Forecast, By Distribution Channel 14.17.1. Hospitals 14.17.2. Clinics 14.17.3. Blood banks 14.18. South America Artificial Blood Market Attractiveness Analysis 14.18.1. By Application 14.18.2. By Distribution Channel 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and Component 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Therapure Biopharma Inc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Sanguine Biosciences 15.3.3. Northfield Laboratories Inc. 15.3.4. Baxter Healthcare Corp. 15.3.5. Alliance Pharmaceutical 15.3.6. FLUORO2 Therapeutics 15.3.7. Alpha Therapeutic Corp. 15.3.8. Kalocyte 15.3.9. Hemarina 15.3.10. Green Cross Corp. 15.3.11. Biopure Corp 15.3.12. Sangart Corporation 16. Primary key Insights

About This Report

Report ID 83548
Category Healthcare
Published Date February 2021
No of Pages 186
Contact Us